Stock Trading History of Barnhill Gregory Hurd
The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
reported to
the Securities and Exchange Commission (SEC)
by insider
Barnhill Gregory Hurd since year 2005.
The trader's CIK number is
1273979.
At the time of this reporting, Barnhill Gregory Hurd is the Director of Pure Bioscience .
(stock ticker symbol
PURE).
See this page for
all insider trading activities at Pure Bioscience .
Note that in the past
BARNHILL GREGORY HURD also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Barnhill Gregory Hurd since 2005.
| Trade Date |
Symbol |
Company Name (Issuer) |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2008-12-29 | PURE | Pure Bioscience | Purchase | 10,000 | 3.02 | 30,203 |
| 2008-10-24 | PURE | Pure Bioscience | Purchase | 3,300 | 2.70 | 8,910 |
| 2008-10-22 | PURE | Pure Bioscience | Purchase | 10,000 | 2.95 | 29,500 |
| 2008-10-23 | PURE | Pure Bioscience | Purchase | 10,000 | 2.95 | 29,500 |
| 2008-10-17 | PURE | Pure Bioscience | Purchase | 10,000 | 3.00 | 30,019 |
| 2008-10-17 | PURE | Pure Bioscience | Purchase | 10,000 | 3.00 | 30,019 |
| 2008-07-02 | PURE | Pure Bioscience | Purchase | 9,830 | 3.87 | 38,042 |
| 2008-06-26 | PURE | Pure Bioscience | Purchase | 10,000 | 4.18 | 41,800 |
| 2008-04-21 | PURE | Pure Bioscience | Purchase | 10,000 | 4.70 | 47,000 |
| 2008-04-07 | PURE | Pure Bioscience | Purchase | 10,000 | 5.72 | 57,170 |
| 2008-04-07 | PURE | Pure Bioscience | Purchase | 10,000 | 5.72 | 57,170 |
| 2008-04-07 | PURE | Pure Bioscience | Purchase | 10,000 | 5.72 | 57,170 |
| 2007-02-05 | OSIR | Osiris Therapeutics, Inc. | Option Exercise | 2,500 | 23.62 | 59,050 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Barnhill Gregory Hurd
(Director of Pure Bioscience at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.
